TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01886794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postmenopausal, topical vaginal estrogen cream
Description: Topical vaginal estrogen cream is commonly but not universally used to improve the health of vaginal tissue prior to surgery. This study will provide data regarding estrogen effects for post-menopausal women undergoing pelvic organ prolapse.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Postmenopausal, topical placebo cream
Description: Postmenopausal participants randomized to topical vaginal placebo for about one month's use prior to scheduled surgery.
Study: NCT01408290

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with FluvalAB
Description: One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
Study: NCT02058368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2mg tablets
Description: Commercially available tamsulosin 0.2mg tablets will be supplied.
Study: NCT04150575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10+Albumin-Bound Paclitaxel
Description: HLX10: 4.5 mg/kg/3w+Albumin-bound paclitaxel: 260 mg/m2/3w.Albumin-bound paclitaxel may be used for up to 6 cycles, and HLX10 for up to 2 years.
Study: NCT03403634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa-2b
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rintatolimod
Description: Given IV
Study: NCT01997775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: METFORMIN
Description: Participants enrolled in this study will be treated with either chemotherapy (Cisplatin 75mg/m2 plus Pemetrexed 500mg/m2 on D1) for 4 cycles or targeted therapy (Gefitinib 250mg/d) till disease progression according to physicians' decision. For participants with plasma IL-6 \> 2.0 pg/mL after 2 cycles of chemotherapy or targeted therapy, Metformin 500mg orally qd will be given on Day 1 of cycle 3. If patient could tolerate it well, metformin will be titrated to 500mg bid in the following week (Cycle 3 D8) and 500mg tid in the 3rd week (Cycle 3 D15). For patients receiving chemotherapy, metformin will be used for total 12 weeks and plasma IL-6 level will be checked at the end of metformin treatment. For patients receiving targeted therapy, metformin will be used till disease progression and plasma IL-6 level will be measured after use of metformin for 12 weeks.
Study: NCT03058406

Intervention type: DRUG
Intervention: Eribulin mesylate
Description: Participants will receive 1.4 milligrams per square meter (mg/m2) administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle and beyond.
Study: NCT00363987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketosteril®
Description: 1 tablet Ketosteril/5kgBW/d

Intervention type: OTHER
Group type: OTHER
Intervention: diabetic diet
Description: Energy 30-35 Kcal/kg BW/d + protein 0.8 g/kg BW/d
Study: NCT00821691

Intervention type: DRUG
Group type: OTHER
Intervention: Amantadin
Description: Amantadin caps

Intervention type: DRUG
Group type: OTHER
Intervention: Amantadin
Description: Amantadin caps

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo caps

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo caps
Study: NCT02058368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disintegrating placebo tamsulosin tablet
Description: Disintegrating placebo tamsulosin tablet will be supplied for the run-in period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disintegrating placebo tamsulosin tablet
Description: Disintegrating placebo tamsulosin tablet will be supplied for the run-in period.
Study: NCT00917059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Fixed dose of 10 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Fixed dose of 10 mg per day
Study: NCT04272099

Intervention type: OTHER
Intervention: Administration of standardized questionnaires
Description: Administration of questionnaires assessing subjective socioeconomic status (SES), health literacy, perceived health, health related quality of life, self-esteem and diabetes self-efficacy

Intervention type: OTHER
Intervention: Administration of standardized questionnaires
Description: Administration of questionnaires assessing subjective socioeconomic status (SES), health literacy, perceived health, health related quality of life, self-esteem and diabetes self-efficacy
Study: NCT00917059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion XL
Description: Fixed dose of 150 mg per day
Study: NCT01879397

Intervention type: DEVICE
Intervention: Research Ultrasound Exam
Description: Collection of backscattered ultrasound data during non-invasive ultrasound exam~* ARFI based images of the carotid artery and plaque~* Ultrasound signals received by the ultrasound imaging system are recorded. These signals are discarded during the image formation process for a standard duplex ultrasound exam.

Intervention type: DEVICE
Intervention: Research Ultrasound Exam
Description: Collection of backscattered ultrasound data during non-invasive ultrasound exam~* ARFI based images of the carotid artery and plaque~* Ultrasound signals received by the ultrasound imaging system are recorded. These signals are discarded during the image formation process for a standard duplex ultrasound exam.
Study: NCT01871948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: We Want to Know campaign, Patient survey at 2 time points
Description: Randomly assigned patients attending cancer clinics at Washington or Georgia sites during February 2013 to August 2013 will be presented with or mailed a survey about cancer communication approximately 2 weeks later and a follow-up survey approximately 3 months later. Additionally, this group will also receive a follow-up phone call approximately 4 weeks after baseline survey.
Study: NCT03864497

Intervention type: PROCEDURE
Intervention: Myocardial perfusion imaging
Study: NCT02605590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIR DNase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIR DNase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIR DNase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03765281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Navigation
Description: Service delivered by clinical Navigator who learns about youth and family's needs and matches to appropriate services.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resource List
Description: Extensive list of mental health and addictions resources, information, and services. Contact information and web links provided for individuals to explore and contact resources of interest.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resource List
Description: Extensive list of mental health and addictions resources, information, and services. Contact information and web links provided for individuals to explore and contact resources of interest.
Study: NCT03110159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levulan® Kerastick®
Description: Levulan® Kerastick® for Topical Solution will be applied to a designated area for 3 hours without occlusion prior to illumination with blue light

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-U Blue Light Photodynamic Therapy
Description: 3 hours after Levulan® Kerastick® for Topical Solution is applied blue light illumination of designated area will be performed using the standard FDA approved treatment time of 16 minutes 40 seconds.
Study: NCT06038682

Intervention type: DRUG
Intervention: Argatroban Injection
Description: Argatroban will be administered to the study subjects in this group in order to achieve anticoagulation.

Intervention type: DRUG
Intervention: Heparin
Description: Heparin will be administered to the study subjects in this group in order to achieve anticoagulation.
Study: NCT04401228

Intervention type: OTHER
Intervention: predict admission of covid-19 patients to ICU and death with routine and quickly avalaible clinical, biological and radiological variables?
Description: patients were questioned about their usual medication (Sartan, angiotensin-converting enzyme inhibitors, nonsteroidal anti-inflammatory drug, immunosuppressive drugs), their health condition (diabetes, hypertension, tobacco use, mental status). The Body mass index was computed.~Age, gender, caucasian/african, weight, body mass index, number of days with symptoms before hospitalization, asthenia, pyrexia, dyspnea, chest pain, digestive sign, anosmia, ageusia, confusion, Travel or contact \< one month, cigarette consumption ,hypertension, diabetes, mental status, angiotensin-converting-enzyme inhibitors, Sartan, non-steroidal anti-inflammatory drugs, immunosuppressive drugs, SpO2,Thoracic Computerized Tomography : % of lung injury, Thoracic Computerized Tomography : density of lung injury, blood type, white blood cells, neutrophils, lymphocytes, blood platelets, fibrinogen, ferritin, triglycerides, LDH, troponin, CRP. The dates of admission to ICU and death were recorded

Intervention type: OTHER
Intervention: predict admission of covid-19 patients to ICU and death with routine and quickly avalaible clinical, biological and radiological variables?
Description: patients were questioned about their usual medication (Sartan, angiotensin-converting enzyme inhibitors, nonsteroidal anti-inflammatory drug, immunosuppressive drugs), their health condition (diabetes, hypertension, tobacco use, mental status). The Body mass index was computed.~Age, gender, caucasian/african, weight, body mass index, number of days with symptoms before hospitalization, asthenia, pyrexia, dyspnea, chest pain, digestive sign, anosmia, ageusia, confusion, Travel or contact \< one month, cigarette consumption ,hypertension, diabetes, mental status, angiotensin-converting-enzyme inhibitors, Sartan, non-steroidal anti-inflammatory drugs, immunosuppressive drugs, SpO2,Thoracic Computerized Tomography : % of lung injury, Thoracic Computerized Tomography : density of lung injury, blood type, white blood cells, neutrophils, lymphocytes, blood platelets, fibrinogen, ferritin, triglycerides, LDH, troponin, CRP. The dates of admission to ICU and death were recorded
Study: NCT01431508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg / HCTZ 12.5 mg
Description: Losartan 50 mg / HCTZ 12.5 mg tablet once daily for 12 weeks
Study: NCT01700816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright light therapy
Description: The light box will be placed vertically on a patient table or bed side 2.5 feet away from the user's eyes daily from 8 am to 8:30 am.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham light
Description: The light box will be placed vertically on a patient table or bed side 2.5 feet away from the user's eyes daily from 8 am to 8:30 am.
Study: NCT01092195

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil
Description: 3 separate 0.5 ml intramuscular
Study: NCT02032446

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC)
Description: pentostatin, dose 1 mg/m2~§ MSC doses:~1. 3 patients → 3 infusions of 1x106 cells /kg~2. 3 patients → 3 infusions of 2x106 cells /kg~3. 3 patients → 3 infusions of 3x106 cells /kg
Study: NCT04272099

Intervention type: DEVICE
Intervention: Physical activity tracker
Description: PG1 will be asked to wear a physical activity tracker for one week to monitor activity patterns including walking distance, calorie expenditure, sedentary time and sleep.

Intervention type: OTHER
Intervention: Dietary log
Description: PG1 (or PG2 as proxies when appropriate) will report to a study coordinator via phone a full dietary log of PG1 once per week on rotating days of the week for three weeks.
Study: NCT02689986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine, Rituximab
Description: Bendamustine, Rituximab
Study: NCT03533829

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Buzzy®
Description: Buzzy® Drug Free Pain Relief which is a medical device designed to reduce vaccination pain when applied to the arm prior to and during a vaccination.
Study: NCT04861753

Intervention type: OTHER
Intervention: Reiki and back massage
Description: In the current study, at the beginning of the treatment, the researcher held his hands 2-3 cm above the patient sand adjusted the aura of the patient by making circular movements from the head to the feet. After this process of aura attunement, the researcher placed his hands directly on the patient's body. In the areas where the practitioner had placed his hands for an average of three minutes, starting from between the eyes, the researcher felt various degrees of warmth and tingling in his palms. Only the back was left exposed to prevent the patient becoming cold. The researcher took a little non-aromatic baby oil in hand and heated it, then began a 20-minute-long massage. The massage consisted of 6.5 minutes of effleurage (stroking), 3.5 minutes of petrissage (kneading), 13 minutes of effleurage and seven minutes of petrissage.

Intervention type: OTHER
Intervention: Reiki and back massage
Description: In the current study, at the beginning of the treatment, the researcher held his hands 2-3 cm above the patient sand adjusted the aura of the patient by making circular movements from the head to the feet. After this process of aura attunement, the researcher placed his hands directly on the patient's body. In the areas where the practitioner had placed his hands for an average of three minutes, starting from between the eyes, the researcher felt various degrees of warmth and tingling in his palms. Only the back was left exposed to prevent the patient becoming cold. The researcher took a little non-aromatic baby oil in hand and heated it, then began a 20-minute-long massage. The massage consisted of 6.5 minutes of effleurage (stroking), 3.5 minutes of petrissage (kneading), 13 minutes of effleurage and seven minutes of petrissage.
Study: NCT03513237

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical dilation
Description: manual dilatation of the cervix using surgeon's finger.
Study: NCT00834509

Intervention type: DEVICE
Intervention: CPAP
Description: Use CPAP for 4-6 weeks as clinically prescribed.
Study: NCT02931864

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online mindfulness training
Description: 5 weekly sessions of online self-administered mindfulness training programme in which they will receive audio-recorded and video-recorded instructions, pictorial or text-based instructions for various mindfulness exercises such as body scan meditation, mindful breathing and walking meditation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online mindfulness training
Description: 5 weekly sessions of online self-administered mindfulness training programme in which they will receive audio-recorded and video-recorded instructions, pictorial or text-based instructions for various mindfulness exercises such as body scan meditation, mindful breathing and walking meditation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online symptom management
Description: 5 weekly online education module in which they will receive video-recorded, audio-recorded, pictorial or text-based instructions for various self-management strategies. Topics include fatigue, pain, numbness/tingling, lymphedema, anxiety/depression, and problems with sleeping.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online symptom management
Description: 5 weekly online education module in which they will receive video-recorded, audio-recorded, pictorial or text-based instructions for various self-management strategies. Topics include fatigue, pain, numbness/tingling, lymphedema, anxiety/depression, and problems with sleeping.
Study: NCT02478944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manometry
Description: Flexible tube catheter pressure measurement of oesophageal contractions. Measurement without any sedation, transnasal
Study: NCT02479620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL
Description: Following atherecomy-based revascularization, Investigators will be unblinded to assignment and will treat only patients assigned to the treatment arm with the Bullfrog delivery of dexamethasone.
Study: NCT02712554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CL-108
Description: 7.5 mg/325 mg/12.5 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CL-108
Description: 7.5 mg/325 mg/12.5 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: M366
Description: 7.5 mg/325 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: M366
Description: 7.5 mg/325 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01316081

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C Vitamin E Selenvital all from Burgerstein Vitamine
Description: Vitamin C: 500mg Vitamin E: 400 I.U. Selenium: 50mcg~Placebo Supplements: identical appearing tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C Vitamin E Selenvital all from Burgerstein Vitamine
Description: Vitamin C: 500mg Vitamin E: 400 I.U. Selenium: 50mcg~Placebo Supplements: identical appearing tablets
Study: NCT01875523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serelaxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serelaxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serelaxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serelaxin
Study: NCT02871011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Delivered as a footbath
Study: NCT02435498

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive website
Description: The interactive website called Online User Centered Home Pain Management for Fractures (OUCH PMF) will cover 4 domains of knowledge: 1. Fracture-related pain 2. Analgesic dosing regimens 3. Indications, risks and safety of analgesia in children 4. Signs and symptoms of pain in children
Study: NCT02871011

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Delivered as a footbath
Study: NCT03049059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional Picosecond 1,064 nm laser
Description: Fractional Picosecond 1,064 nm laser and daily application with 4% hydroquinone cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4% hydroquinone cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% hydroquinone cream
Study: NCT01609556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine
Description: Mirvetuximab soravtansine IV infusion will be administered as per dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine
Description: Mirvetuximab soravtansine IV infusion will be administered as per dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine
Description: Mirvetuximab soravtansine IV infusion will be administered as per dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine
Description: Mirvetuximab soravtansine IV infusion will be administered as per dose and schedule specified in the respective arms.
Study: NCT03533829

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Buzzy®
Description: Buzzy® Drug Free Pain Relief which is a medical device designed to reduce vaccination pain when applied to the arm prior to and during a vaccination.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Music will be selected and listened to as a distraction before and during vaccination.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Music will be selected and listened to as a distraction before and during vaccination.
Study: NCT02198547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Mg used with ropivacaine for sciatic nerve blick

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine 7,5 mg/ml used for sciatic nerve block
Study: NCT05792449

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Foundational Skills Curriculum
Description: The therapist will coach parents in the context of clinic-based play activities and help parents identify contexts and activities at home where the parents could follow up on the program at home. Intervention sessions empower and equip parents with skills and strategies to engage with their child at home. Since the program involves behavioural intervention and parent coaching, active participation of parent and child are key to each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Foundational Skills Curriculum - Telerehabilitation
Description: Parent-child interactions during activities at home will be observed through video conferencing. Parents will be encouraged to interact with their child using strategies aimed at increasing their child's attention and motivation, turn-taking routines, initiating and responding to joint attention, communication, etc. Intervention sessions empower and equip parents with skills and strategies to engage with their child at home. Since the program involves behavioural intervention and parent coaching, active participation of parent and child are key to each session.
Study: NCT02592733

Intervention type: DEVICE
Intervention: CYDAR
Description: CYDAR is an automated image mask that is cloud based adn delivered to operating theatres over a secure network. It fuses preoperative images with intraoperative images to provide more accurate image guidance for the surgeon.